Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 2) - Журнал Терапевтический архив №4 Вопросы диагностики внутренних болезней 2021
Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 2)
Райхельсон К.Л., Кондрашина Э.А., Пазенко Е.В. Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 2). Терапевтический архив. 2021; 93 (4): 516–520. DOI: 10.26442/00403660.2021.04.200755
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре обсуждаются эпидемиологические и патогенетические аспекты сочетания стеатогепатитов (СГ) смешанного генеза, обусловленных неалкогольной жировой болезнью печени (метаболически ассоциированная жировая болезнь печени), алкогольной болезнью печени, лекарственным поражением печени. Проанализированы патогенетические механизмы взаимоотягчающего влияния этиологических факторов. Лекарственные средства могут вызывать стеатоз и СГ, а также способствовать прогрессирующему течению уже имеющегося СГ, прежде всего метаболического характера. Рассмотрены вопросы взаимодействия патогенетических факторов, особенности диагностики и перспективные возможности патогенетического и симптоматического лечения. Основой терапии СГ смешанного генеза являются отмена гепатотоксических лекарственных препаратов и модификация образа жизни, в качестве медикаментозного лечения следует использовать препараты, показавшие свою эффективность при отдельных вариантах СГ (такие как адеметионин).
Ключевые слова: стеатогепатит, неалкогольная жировая болезнь печени, метаболически ассоциированная жировая болезнь печени, алкогольная болезнь печени, лекарственное поражение печени, адеметионин
Keywords: steatohepatitis, non-alcoholic fatty liver disease, metabolic associated fatty liver disease, drug-induced liver injury, ademetionine
Ключевые слова: стеатогепатит, неалкогольная жировая болезнь печени, метаболически ассоциированная жировая болезнь печени, алкогольная болезнь печени, лекарственное поражение печени, адеметионин
________________________________________________
Keywords: steatohepatitis, non-alcoholic fatty liver disease, metabolic associated fatty liver disease, drug-induced liver injury, ademetionine
Список литературы
1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004
2. Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:218-25.
doi: 10.1007/s00535-018-01542-w
3. Райхельсон К.Л., Кондрашина Э.А., Пазенко Е.В. Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 1). Терапевтический архив. 2020;92(12):91-6 [Raikhelson KL, Kondrashina EA, Pazenko EV. Mixed steatohepatitis: more questions than answers (Part 1). Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(12):91-6 (In Russ.)]. doi: 10.26442/00403660.2020.12.200470
4. Chalasani NP, Chalasani NP, Hayashi PH, et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66. doi: 10.1038/ajg.2014.131
5. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115-22. doi: 10.1055/s-0034-1375953
6. Переверзев А.П., Остроумова О.Д. Лекарственно-ассоциированная жировая болезнь печени. Безопасность и риск фармакотерапии. 2020;8(2):66-76 [Pereverzev AP, Ostroumova OD. Drug-induced fatty liver disease. Bezopasnost’ i risk farmakoterapii. 2020;8(2):66-76 (In Russ.)]. doi: 10.30895/2312-7821-2020-8-2-66-76
7. Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85-115 [Ivashkin VT, Baranovsky AYu, Raikhelson KL, et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2019;29(1):85-115 (In Russ.)]. doi: 10.22416/1382-4376-2019-29-1-101-131
8. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-21. doi: 10.1053/j.gastro.2005.05.006
9. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661-70. doi: 10.1002/hep.26709
10. Satapathy SK, Kuwajima V, Nadelson J, et al. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789-806. doi: 10.5604/16652681.1171749
11. Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9(5):261-3.
12. Grieco A, Alfei B, Rocco PDI, et al. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol. 2001;13:973-5.
13. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol. 2004;16(6):593-8. doi: 10.1097/00042737-200406000-00013
14. Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. BioMed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905
15. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. doi: 10.1016/j.mito.2005.10.004
16. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handbook of Experimental Pharmacology. 2010;196:311-65. doi: 10.1007/978-3-642-00663-0_11
17. Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016
18. Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43(3):317-34. doi: 10.3109/03602532.2011.577781
19. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. doi: 10.1016/j.jhep.2019.02.014
20. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Exp Rev Gastroenterol Hepatol. 2011;5:233-44. doi: 10.1586/egh.11.11
21. Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773-94. doi: 10.1016/j.jhep.2010.11.006
22. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335-53. doi: 10.1111/j.1472-8206.2008.00608
23. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139-150. doi: 10.1038/nrrheum.2010.214
24. Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci. 2014;15(3):4019-30. doi: 10.3390/ijms15034019
25. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932. doi: 10.1136/bmj.38391.663287.E0
26. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115(14):3189-95. doi: 10.1002/cncr.24374
27. Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Therapeut. 2014;40:938-48. doi: 10.1111/apt.12912
28. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111-8. doi: 10.1016/j.jhep.2007.01.024
29. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
J Hepatol. 2010;53:1035-40. doi: 10.1016/j.jhep.2010.04.043
30. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5(3):199-207.
doi: 10.1177/1756283X11430859
31. Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 2014;66(8):1159-66. doi: 10.1002/acr.22294
32. Zimmerman HJ. Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res. 1986;10:3-15. doi: 10.1111/j.1530-0277.1986.tb05605
33. Dakhoul L, Ghabril M, Gu J, et al. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16:722-9. doi: 10.1016/j.cgh.2017.12.036
34. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34.e1-4. doi: 0.1053/j.gastro.2008.09.011
35. Лазебник Л.Б., Голованова Е.В., Хлынова О.В., и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29-54 [Lazebnik LB, Golovanova EV, Hlynova OV, et al. Medicinal liver damage in adults. Eksperimental’naya i klinicheskaya gastroenterologiya. 2020;174(2):29-54 (In Russ.)]. doi: 10.3114 6/168 2-8658-ecg-174-2-29-54
36. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331-6. doi: 10.1016/0895-4356(93)90102-7
37. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14. doi: 10.3390/ijms17010014
38. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. II. Addiction. 1993;88:791-804.
39. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
40. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21-9. doi: 10.2147/PTT.S141629
41. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):20–40 [Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(6):20-40 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-6-20-40
42. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81. doi: 10.1016/j.jhep.2018.03.018
43. Alkhouri N, Scott A. An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications. Clin Liver Dis. 2018;11(4):82-6. doi: 10.1002/cld.708
44. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;2:24-42 [Ivashkin VT, Maevskaja MV, Pavlov ChS, et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;2:24-42 (In Russ.)]. doi: 10.22416/1382-4376-2016-26-2-24-42
45. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78. doi: 10.1053/j.gastro.2015.04.005
46. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-46. doi: 10.1016/j.jhep.2017.05.016
47. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94. doi: 10.1038/ajg.2017.469
48. Woodhead JL, Howell BA, Yang Y, et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529-40. doi: 10.1124/jpet.112.192930
49. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206-10. doi: 10.1097/mop.0b013e32805e879a
50. Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapyinduced liver injury. Anticancer Res. 2003;23(6D):5173-79.
51. Снеговой А.В., Ларионова В.Б., Зейналова П.А., и др. Окончательные результаты проспективной многоцентровой программы Р12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарственно-индуцированным поражением печени вследствие химиотерапии). Вестник Российского онкологического научного центра имени Н.Н. Блохина РАМН. 2016;27(2):142-56 [Snegovoy AV, Larionova VB, Zeynalova PA, et al. Final Results Prospective, Multicenter Program P12-717 (Same application in chronic liver disease, conditionality of drug-induced liver injury due to chemotherapy). Vestnik RONTs im. N.N. Blokhina RMN (Herald of Russian Oncological Research Center named after N.N. Blokhin). 2016;27(2):142-56 (In Russ.)].
52. Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients a-ected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345-9. doi: 10.1517/14740338.2011.562888
53. Mato JM, Cámara J, Fernández de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-9. doi: 10.1016/s0168-8278(99)80263-3
54. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482-93: doi: 10.18203/2320-6012.ijrms20192550
55. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood).2015;240(6):809-20. doi: 10.1177/1535370215579161
56. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041
2. Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:218-25.
doi: 10.1007/s00535-018-01542-w
3. Raikhelson KL, Kondrashina EA, Pazenko EV. Mixed steatohepatitis: more questions than answers (Part 1). Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(12):91-6 (In Russ.) doi: 10.26442/00403660.2020.12.200470
4. Chalasani NP, Chalasani NP, Hayashi PH, et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66. doi: 10.1038/ajg.2014.131
5. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115-22. doi: 10.1055/s-0034-1375953
6. Pereverzev AP, Ostroumova OD. Drug-induced fatty liver disease. Bezopasnost’ i risk farmakoterapii. 2020;8(2):66-76 (In Russ.) doi: 10.30895/2312-7821-2020-8-2-66-76
7. Ivashkin VT, Baranovsky AYu, Raikhelson KL, et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2019;29(1):85-115 (In Russ.) doi: 10.22416/1382-4376-2019-29-1-101-131
8. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-21. doi: 10.1053/j.gastro.2005.05.006
9. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661-70. doi: 10.1002/hep.26709
10. Satapathy SK, Kuwajima V, Nadelson J, et al. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789-806. doi: 10.5604/16652681.1171749
11. Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9(5):261-3.
12. Grieco A, Alfei B, Rocco PDI, et al. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol. 2001;13:973-5.
13. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol. 2004;16(6):593-8. doi: 10.1097/00042737-200406000-00013
14. Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. BioMed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905
15. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. doi: 10.1016/j.mito.2005.10.004
16. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handbook of Experimental Pharmacology. 2010;196:311-65. doi: 10.1007/978-3-642-00663-0_11
17. Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016
18. Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43(3):317-34. doi: 10.3109/03602532.2011.577781
19. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. doi: 10.1016/j.jhep.2019.02.014
20. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Exp Rev Gastroenterol Hepatol. 2011;5:233-44. doi: 10.1586/egh.11.11
21. Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773-94. doi: 10.1016/j.jhep.2010.11.006
22. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335-53. doi: 10.1111/j.1472-8206.2008.00608
23. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139-150. doi: 10.1038/nrrheum.2010.214
24. Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci. 2014;15(3):4019-30. doi: 10.3390/ijms15034019
25. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932. doi: 10.1136/bmj.38391.663287.E0
26. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115(14):3189-95. doi: 10.1002/cncr.24374
27. Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Therapeut. 2014;40:938-48. doi: 10.1111/apt.12912
28. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111-8. doi: 10.1016/j.jhep.2007.01.024
29. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
J Hepatol. 2010;53:1035-40. doi: 10.1016/j.jhep.2010.04.043
30. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5(3):199-207.
doi: 10.1177/1756283X11430859
31. Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 2014;66(8):1159-66. doi: 10.1002/acr.22294
32. Zimmerman HJ. Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res. 1986;10:3-15. doi: 10.1111/j.1530-0277.1986.tb05605
33. Dakhoul L, Ghabril M, Gu J, et al. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16:722-9. doi: 10.1016/j.cgh.2017.12.036
34. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34.e1-4. doi: 0.1053/j.gastro.2008.09.011
35. Lazebnik LB, Golovanova EV, Hlynova OV, et al. Medicinal liver damage in adults. Eksperimental’naya i klinicheskaya gastroenterologiya. 2020;174(2):29-54 (In Russ.)
doi: 10.3114 6/168 2-8658-ecg-174-2-29-54
36. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331-6. doi: 10.1016/0895-4356(93)90102-7
37. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14. doi: 10.3390/ijms17010014
38. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. II. Addiction. 1993;88:791-804.
39. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
40. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21-9. doi: 10.2147/PTT.S141629
41. Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(6):20-40 (In Russ.) doi: 10.22416/1382-4376-2017-27-6-20-40
42. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81. doi: 10.1016/j.jhep.2018.03.018
43. Alkhouri N, Scott A. An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications. Clin Liver Dis. 2018;11(4):82-6. doi: 10.1002/cld.708
44. Ivashkin VT, Maevskaja MV, Pavlov ChS, et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;2:24-42 (In Russ.) doi: 10.22416/1382-4376-2016-26-2-24-42
45. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78. doi: 10.1053/j.gastro.2015.04.005
46. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-46. doi: 10.1016/j.jhep.2017.05.016
47. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94. doi: 10.1038/ajg.2017.469
48. Woodhead JL, Howell BA, Yang Y, et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529-40. doi: 10.1124/jpet.112.192930
49. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206-10. doi: 10.1097/mop.0b013e32805e879a
50. Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapyinduced liver injury. Anticancer Res. 2003;23(6D):5173-79.
51. Snegovoy AV, Larionova VB, Zeynalova PA, et al. Final Results Prospective, Multicenter Program P12-717 (Same application in chronic liver disease, conditionality of drug-induced liver injury due to chemotherapy). Vestnik RONTs im. N.N. Blokhina RMN (Herald of Russian Oncological Research Center named after N.N. Blokhin). 2016;27(2):142-56 (In Russ.)
52. Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients a-ected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345-9. doi: 10.1517/14740338.2011.562888
53. Mato JM, Cámara J, Fernández de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-9. doi: 10.1016/s0168-8278(99)80263-3
54. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482-93: doi: 10.18203/2320-6012.ijrms20192550
55. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood).2015;240(6):809-20. doi: 10.1177/1535370215579161
56. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041
2. Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:218-25.
doi: 10.1007/s00535-018-01542-w
3. Райхельсон К.Л., Кондрашина Э.А., Пазенко Е.В. Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 1). Терапевтический архив. 2020;92(12):91-6 [Raikhelson KL, Kondrashina EA, Pazenko EV. Mixed steatohepatitis: more questions than answers (Part 1). Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(12):91-6 (In Russ.)]. doi: 10.26442/00403660.2020.12.200470
4. Chalasani NP, Chalasani NP, Hayashi PH, et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66. doi: 10.1038/ajg.2014.131
5. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115-22. doi: 10.1055/s-0034-1375953
6. Переверзев А.П., Остроумова О.Д. Лекарственно-ассоциированная жировая болезнь печени. Безопасность и риск фармакотерапии. 2020;8(2):66-76 [Pereverzev AP, Ostroumova OD. Drug-induced fatty liver disease. Bezopasnost’ i risk farmakoterapii. 2020;8(2):66-76 (In Russ.)]. doi: 10.30895/2312-7821-2020-8-2-66-76
7. Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л., и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85-115 [Ivashkin VT, Baranovsky AYu, Raikhelson KL, et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2019;29(1):85-115 (In Russ.)]. doi: 10.22416/1382-4376-2019-29-1-101-131
8. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-21. doi: 10.1053/j.gastro.2005.05.006
9. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661-70. doi: 10.1002/hep.26709
10. Satapathy SK, Kuwajima V, Nadelson J, et al. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789-806. doi: 10.5604/16652681.1171749
11. Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9(5):261-3.
12. Grieco A, Alfei B, Rocco PDI, et al. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol. 2001;13:973-5.
13. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol. 2004;16(6):593-8. doi: 10.1097/00042737-200406000-00013
14. Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. BioMed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905
15. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. doi: 10.1016/j.mito.2005.10.004
16. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handbook of Experimental Pharmacology. 2010;196:311-65. doi: 10.1007/978-3-642-00663-0_11
17. Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016
18. Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43(3):317-34. doi: 10.3109/03602532.2011.577781
19. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. doi: 10.1016/j.jhep.2019.02.014
20. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Exp Rev Gastroenterol Hepatol. 2011;5:233-44. doi: 10.1586/egh.11.11
21. Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773-94. doi: 10.1016/j.jhep.2010.11.006
22. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335-53. doi: 10.1111/j.1472-8206.2008.00608
23. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139-150. doi: 10.1038/nrrheum.2010.214
24. Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci. 2014;15(3):4019-30. doi: 10.3390/ijms15034019
25. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932. doi: 10.1136/bmj.38391.663287.E0
26. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115(14):3189-95. doi: 10.1002/cncr.24374
27. Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Therapeut. 2014;40:938-48. doi: 10.1111/apt.12912
28. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111-8. doi: 10.1016/j.jhep.2007.01.024
29. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
J Hepatol. 2010;53:1035-40. doi: 10.1016/j.jhep.2010.04.043
30. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5(3):199-207.
doi: 10.1177/1756283X11430859
31. Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 2014;66(8):1159-66. doi: 10.1002/acr.22294
32. Zimmerman HJ. Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res. 1986;10:3-15. doi: 10.1111/j.1530-0277.1986.tb05605
33. Dakhoul L, Ghabril M, Gu J, et al. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16:722-9. doi: 10.1016/j.cgh.2017.12.036
34. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34.e1-4. doi: 0.1053/j.gastro.2008.09.011
35. Лазебник Л.Б., Голованова Е.В., Хлынова О.В., и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29-54 [Lazebnik LB, Golovanova EV, Hlynova OV, et al. Medicinal liver damage in adults. Eksperimental’naya i klinicheskaya gastroenterologiya. 2020;174(2):29-54 (In Russ.)]. doi: 10.3114 6/168 2-8658-ecg-174-2-29-54
36. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331-6. doi: 10.1016/0895-4356(93)90102-7
37. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14. doi: 10.3390/ijms17010014
38. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. II. Addiction. 1993;88:791-804.
39. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
40. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21-9. doi: 10.2147/PTT.S141629
41. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):20–40 [Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(6):20-40 (In Russ.)]. doi: 10.22416/1382-4376-2017-27-6-20-40
42. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81. doi: 10.1016/j.jhep.2018.03.018
43. Alkhouri N, Scott A. An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications. Clin Liver Dis. 2018;11(4):82-6. doi: 10.1002/cld.708
44. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;2:24-42 [Ivashkin VT, Maevskaja MV, Pavlov ChS, et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;2:24-42 (In Russ.)]. doi: 10.22416/1382-4376-2016-26-2-24-42
45. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78. doi: 10.1053/j.gastro.2015.04.005
46. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-46. doi: 10.1016/j.jhep.2017.05.016
47. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94. doi: 10.1038/ajg.2017.469
48. Woodhead JL, Howell BA, Yang Y, et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529-40. doi: 10.1124/jpet.112.192930
49. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206-10. doi: 10.1097/mop.0b013e32805e879a
50. Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapyinduced liver injury. Anticancer Res. 2003;23(6D):5173-79.
51. Снеговой А.В., Ларионова В.Б., Зейналова П.А., и др. Окончательные результаты проспективной многоцентровой программы Р12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарственно-индуцированным поражением печени вследствие химиотерапии). Вестник Российского онкологического научного центра имени Н.Н. Блохина РАМН. 2016;27(2):142-56 [Snegovoy AV, Larionova VB, Zeynalova PA, et al. Final Results Prospective, Multicenter Program P12-717 (Same application in chronic liver disease, conditionality of drug-induced liver injury due to chemotherapy). Vestnik RONTs im. N.N. Blokhina RMN (Herald of Russian Oncological Research Center named after N.N. Blokhin). 2016;27(2):142-56 (In Russ.)].
52. Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients a-ected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345-9. doi: 10.1517/14740338.2011.562888
53. Mato JM, Cámara J, Fernández de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-9. doi: 10.1016/s0168-8278(99)80263-3
54. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482-93: doi: 10.18203/2320-6012.ijrms20192550
55. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood).2015;240(6):809-20. doi: 10.1177/1535370215579161
56. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041
________________________________________________
2. Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54:218-25.
doi: 10.1007/s00535-018-01542-w
3. Raikhelson KL, Kondrashina EA, Pazenko EV. Mixed steatohepatitis: more questions than answers (Part 1). Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(12):91-6 (In Russ.) doi: 10.26442/00403660.2020.12.200470
4. Chalasani NP, Chalasani NP, Hayashi PH, et al. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66. doi: 10.1038/ajg.2014.131
5. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115-22. doi: 10.1055/s-0034-1375953
6. Pereverzev AP, Ostroumova OD. Drug-induced fatty liver disease. Bezopasnost’ i risk farmakoterapii. 2020;8(2):66-76 (In Russ.) doi: 10.30895/2312-7821-2020-8-2-66-76
7. Ivashkin VT, Baranovsky AYu, Raikhelson KL, et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2019;29(1):85-115 (In Russ.) doi: 10.22416/1382-4376-2019-29-1-101-131
8. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-21. doi: 10.1053/j.gastro.2005.05.006
9. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661-70. doi: 10.1002/hep.26709
10. Satapathy SK, Kuwajima V, Nadelson J, et al. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789-806. doi: 10.5604/16652681.1171749
11. Grieco A, Forgione A, Miele L, et al. Fatty liver and drugs. Eur Rev Med Pharmacol Sci. 2005;9(5):261-3.
12. Grieco A, Alfei B, Rocco PDI, et al. Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol. 2001;13:973-5.
13. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol. 2004;16(6):593-8. doi: 10.1097/00042737-200406000-00013
14. Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. BioMed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905
15. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. doi: 10.1016/j.mito.2005.10.004
16. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handbook of Experimental Pharmacology. 2010;196:311-65. doi: 10.1007/978-3-642-00663-0_11
17. Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016
18. Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43(3):317-34. doi: 10.3109/03602532.2011.577781
19. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. doi: 10.1016/j.jhep.2019.02.014
20. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Exp Rev Gastroenterol Hepatol. 2011;5:233-44. doi: 10.1586/egh.11.11
21. Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54:773-94. doi: 10.1016/j.jhep.2010.11.006
22. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335-53. doi: 10.1111/j.1472-8206.2008.00608
23. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139-150. doi: 10.1038/nrrheum.2010.214
24. Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. Int J Mol Sci. 2014;15(3):4019-30. doi: 10.3390/ijms15034019
25. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932. doi: 10.1136/bmj.38391.663287.E0
26. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115(14):3189-95. doi: 10.1002/cncr.24374
27. Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Therapeut. 2014;40:938-48. doi: 10.1111/apt.12912
28. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111-8. doi: 10.1016/j.jhep.2007.01.024
29. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
J Hepatol. 2010;53:1035-40. doi: 10.1016/j.jhep.2010.04.043
30. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5(3):199-207.
doi: 10.1177/1756283X11430859
31. Schmajuk G, Miao Y, Yazdany J, et al. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res. 2014;66(8):1159-66. doi: 10.1002/acr.22294
32. Zimmerman HJ. Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res. 1986;10:3-15. doi: 10.1111/j.1530-0277.1986.tb05605
33. Dakhoul L, Ghabril M, Gu J, et al. Heavy consumption of alcohol is not associated with worse outcomes in patients with idiosyncratic drug-induced liver injury compared to non-drinkers. Clin Gastroenterol Hepatol. 2018;16:722-9. doi: 10.1016/j.cgh.2017.12.036
34. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34.e1-4. doi: 0.1053/j.gastro.2008.09.011
35. Lazebnik LB, Golovanova EV, Hlynova OV, et al. Medicinal liver damage in adults. Eksperimental’naya i klinicheskaya gastroenterologiya. 2020;174(2):29-54 (In Russ.)
doi: 10.3114 6/168 2-8658-ecg-174-2-29-54
36. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331-6. doi: 10.1016/0895-4356(93)90102-7
37. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14. doi: 10.3390/ijms17010014
38. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. II. Addiction. 1993;88:791-804.
39. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
40. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21-9. doi: 10.2147/PTT.S141629
41. Ivashkin VT, Mayevskaya MV, Pavlov ChS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(6):20-40 (In Russ.) doi: 10.22416/1382-4376-2017-27-6-20-40
42. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-81. doi: 10.1016/j.jhep.2018.03.018
43. Alkhouri N, Scott A. An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications. Clin Liver Dis. 2018;11(4):82-6. doi: 10.1002/cld.708
44. Ivashkin VT, Maevskaja MV, Pavlov ChS, et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;2:24-42 (In Russ.) doi: 10.22416/1382-4376-2016-26-2-24-42
45. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78. doi: 10.1053/j.gastro.2015.04.005
46. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-46. doi: 10.1016/j.jhep.2017.05.016
47. Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-94. doi: 10.1038/ajg.2017.469
48. Woodhead JL, Howell BA, Yang Y, et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012;342(2):529-40. doi: 10.1124/jpet.112.192930
49. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19(2):206-10. doi: 10.1097/mop.0b013e32805e879a
50. Santini D, Vincenzi B, Massacesi C, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapyinduced liver injury. Anticancer Res. 2003;23(6D):5173-79.
51. Snegovoy AV, Larionova VB, Zeynalova PA, et al. Final Results Prospective, Multicenter Program P12-717 (Same application in chronic liver disease, conditionality of drug-induced liver injury due to chemotherapy). Vestnik RONTs im. N.N. Blokhina RMN (Herald of Russian Oncological Research Center named after N.N. Blokhin). 2016;27(2):142-56 (In Russ.)
52. Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients a-ected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345-9. doi: 10.1517/14740338.2011.562888
53. Mato JM, Cámara J, Fernández de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-9. doi: 10.1016/s0168-8278(99)80263-3
54. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7(6):2482-93: doi: 10.18203/2320-6012.ijrms20192550
55. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood).2015;240(6):809-20. doi: 10.1177/1535370215579161
56. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041
Авторы
К.Л. Райхельсон*, Э.А. Кондрашина, Е.В. Пазенко
ФГБОУ ВО «Санкт-Петербургский государственный университет», Санкт-Петербург, Россия
*kraikhelson@mail.ru
Saint Petersburg State University, Saint Petersburg, Russia
*kraikhelson@mail.ru
ФГБОУ ВО «Санкт-Петербургский государственный университет», Санкт-Петербург, Россия
*kraikhelson@mail.ru
________________________________________________
Saint Petersburg State University, Saint Petersburg, Russia
*kraikhelson@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.